Havana, – The Center for Genetic Engineering and Biotechnology of Cuba (CIGB) today highlighted the excellent results of the efficacy and effectiveness of Abdallah’s vaccine, the first in Latin America against Covid-19.
“In 2021, excellent results were obtained for the effectiveness and efficacy of Abdallah from the CIGB against symptomatic diseases, severe forms and death, which allowed its continued use in Cuba,” confirms a message from the Foundation on the social network Twitter.
Another note from the CIGB notes that phase II and III clinical studies of the drug ended this year, with an efficacy of 92.28 percent.
“The health vaccination intervention against Covid-19 has been implemented in several municipalities in Havana and its emergency use has been extended in Cuba,” the entity adds.
Likewise, “in 2021, a Phase 1 clinical study concluded with Mambisa as a booster in COVID-19 convalescent patients, comparing three devices for nasal administration,” the CIGB recalls.
In another message, the entity commented, “Phase II studies have begun to determine the efficacy and ‘Bakunau’ as a booster dose in those vaccinated with Abdullah.”
This year, Jusvinza, the first Cuban drug based on the synthesis of a peptide included in the protocol of action in Cuba for the treatment of serious and critical Covid-19 patients, has reduced mortality.
The CIGB highlighted its “researchers have published five scientific articles”.
The Foundation also confirmed that vaccination against Covid-19 promotes pregnancy with fewer risks.
“Caring for the organism that has been developed is a priority. By vaccinating, we are reducing that unwanted infection puts this life project at risk,” warned the emblematic scientific entity.
“Unapologetic tv specialist. Hardcore zombie trailblazer. Infuriatingly humble problem solver.”